National Implementation Report Now Available

[vc_row][vc_column][vc_column_text]The first National Implementation report has now been published. The report follows up the first five EUnetHTA assessments to be published. For these assessments, 46 examples of use have been reported, including both use to support assessment procedures and use as part of dissemination to support awareness of HTA for decision making purposes. As well […]

OTCA12 “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” Final Project Plan Now Available

This is the final project plan of the assessment on C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) and the comments provided by external experts during scoping. OTCA12_Final-project-plan.pdf OTCA12_Draft-project-plan_collated-comments-from-external-experts_fact_check_manufacturers.pdf

EMA-EUnetHTA Meeting December 2017 – Final Minutes

EMA-EUnetHTA meeting December 2017 – Final minutes [pdf-embedder url=”https://www.eunethta.eu/wp-content/uploads/2018/04/EMA-EUnetHTA-meeting-Dec-2017-minutes-.pdf” title=”EMA-EUnetHTA meeting Dec 2017 minutes”]

OTCA09 “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” is now available

We are pleased to announce publication of the collaborative assessment OTCA09 “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer”. This is the assessment of the relative effectiveness of high-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer. The purpose of the assessment is to evaluate the relative effectiveness and safety […]

OTCA09 “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” Final Project Plan Now Available

[vc_row][vc_column][vc_column_text]This is the final project plan of the assessment on “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” and the comments provided by an external expert during scoping. Project Plan_HIFU_final Project Plan external reviewer comments and authors’ answers[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row]

OTJA08 Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin

The final project plan of the assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems” and the comments provided by the external experts and the manufacturers are now available. OTJA08_Project_Plan_CGM_and_FGM OTJA08_Compiled_comments_answers_PP_external_experts_manufacturers

Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery

Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery This is the final project plan of the assessment on “Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery” and the comments provided by one manufacturer during a fact check of the draft project plan. Project […]

WP4 PTJA03 on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)” is now available

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”. This is a revised version of the report originally posted on January 23, 2018. An error was identified in table 0.1 and table A21, in which […]

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.